Last checked at 19 Jun 2014 17:35
For immediate release | 19 June 2014 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Exercise of Share Options
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that following the exercise of employee share options on 19 June 2014, application has been made by Alliance for a further 10,492 ordinary shares of 1 pence each in the Company ("Ordinary Shares") to be admitted to trading on AIM.
It is expected that these new Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares, will be admitted to trading on 25 June 2014.
Following the exercise of the options, Alliance will have 264,148,365 Ordinary Shares in issue.
For further information:
Alliance Pharma plc | + 44 (0) 1249 466966 |
John Dawson, Chief Executive | |
Richard Wright, Finance Director | |
| |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles | |
Numis Securities Limited | + 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Oliver Cardigan/Freddie Barnfield | |
Corporate Broking: David Poutney |
Notes to editors:
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.